Navigation Links
Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Date:9/20/2007

Agreement demonstrates broad potential use of Intellect's clinical

candidate

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on the development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, and CHDI, Inc., a non-profit organization pursuing the discovery and development of drugs to prevent or slow the progression of Huntington disease (HD), announced today that they have entered into an agreement under which CHDI will assess Intellect's OXIGON(TM) as a potential therapy for Huntington disease. CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models. Intellect has completed Phase I clinical trials for OXIGON(TM) in elderly healthy volunteers.

Dr. Daniel Chain, CEO and Chairman of Intellect, commented: "We are pleased that CHDI is evaluating whether OXIGON's method of action might extend to Huntington disease. OXIGON(TM) is planned to enter Phase II clinical trials in Alzheimer's patients in 2008. The data generated in the CHDI study could support proceeding with clinical trials in HD patients as well."

"We are intrigued by the properties of this compound, which has demonstrated neuroprotective effects in various animal models," said Robert Pacifici, CHDI's Chief Scientific Officer. "We are pleased to work with the Intellect team to evaluate the usefulness of OXIGON(TM) to treat HD."

About OXIGON(TM)

Intellect's lead drug candidate, OXIGON(TM), is a chemically synthesized form of a naturally occurring molecule that has unique neuroprotectant and antioxidant properties. OXIGON(TM) has been demonstrated to protect the brain from many potent neurotoxins in animals and also to block the formation of toxic aggregates that result from abnormal folding of proteins such as beta amyloid
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)
6. M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
9. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
10. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
11. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... Showed Larazotide Acetate Prevented Immunologic C...ts with Celiac Disease, Additional Data Indicates ... ORLANDO, Fla., Oct. 7 /- Alba Therap...ical studies this week at the American,College of ...ing. Data from,study CLIN 1001-004, the first Phas...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Scientific ...tCall/ -- Ironwood,Pharmaceuticals, Inc. (formerly...SE: FRX ) today announced the presentation of res... safety and efficacy in 420 patients with,irritabl...is of the data,indicates that once- daily oral dos...
(Date:10/7/2008)...ient, Prospective Randomized Placebo-Controlled Ph...ant Improved Overall Survival., MOUNTAIN VIEW, Ca...peutics has now evaluated the mature Phase II data...idate PROSTVAC(TM) that had been,obtained as part ...nal,Cancer Institute (NCI) in the US., The result...
(Date:10/7/2008)...STGÃ…RD, Denmark, October 7 /PRNewswire-FirstCall/...o-Controlled Phase II Study,Shows Statistically Si...dic has now evaluated the mature phase II data fro...e PROSTVAC(TM) that had been,obtained as part of t...Cancer Institute (NCI) in the US., The results fr...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5NIST announces 56 new awards for innovative technology research and development 604 1iCAD to Present at William Blair 26 Company Small Cap Growth Stock Conference 2321 1iCAD to Present at William Blair 26 Company Small Cap Growth Stock Conference 2321 2President Bush Should Protect Kids Not Big Tobacco By Signing Bill to Increase Cigarette Tax Fund SCHIP 2318 1President Bush Should Protect Kids Not Big Tobacco By Signing Bill to Increase Cigarette Tax Fund SCHIP 2318 2Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals 932 1Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals 932 2
(Date:10/7/2008)...ltrasound similar to more expensive whole-leg colo...AY, Oct. 7 (HealthDay News) -- An older, simpler t...eep vein thrombosis, or DVT -- is as effective as ..., European researchers found that 2-point ultras...on or duplex ultrasound -- was as good at detectin...
(Date:10/7/2008)...riz., Oct. 7 /PRNewswire/ -- Join Mii amo, a desti...elebration in Sedona,s red rock,country honoring t...ude a,series of traditional Native American ceremo...or R.J. Joseph and special guest, Elder George,Goo...oot Elder from the Blood Reserve,in Standoff, Albe...
(Date:10/7/2008)... 100,000 PEOPLE ACROSS THE NATION HAVE SAID ,I VOT... DALLAS, Oct. 7 /PRNewswire/ -- To aid and help e...out the positions of presidential candidates,Senat...e and cancer issues,the Susan G. Komen for the Cu... resources available on its web site --, http://ww...
(Date:10/7/2008)...N, Oct. 7 /PRNewswire-USNewswire/ -- The Catholic ...n conjunction with Catholic,Health Initiatives (CH...;,and Trinity Health, Novi, MI -- is launching a m...l climate change., Through receipt of a $20,000 g...he Environment (NRPE) and the Catholic Coalition o...
Breaking Medicine News(10 mins):Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3Health News:Catholic Health Organizations Launch Ministry-Wide Effort to Raise Awareness About Global Climate Change 2
...sts have developed a scan that could spot the earl...ated illness.// The new machine, which uses techno...of liver damage drinkers may be doing themselves, ...n of Daily Mail. Until now damage could be accurat...
...ing fatty dairy products may actually help in slim... specialists have cautioned people to be wary of s...nvolved in this study. At the end of this study, i...fat free milk had put on more weight when compared...
...re many agencies which are involved in different k...research findings. Each agency may come out with d...the funding agency. In this connection, Dr. David...nd Harvard University says that there are numerous...
...ampsia, an extremely undesirable condition in preg...and child. The condition is said to claim the live...scientists have devised a new diagnostic evaluatio...cting the condition early and saving lives. The r...
Other Medicine News:
...Intermec has an installed base of field-proven bar...spital departments using Intermec media include; r...y, Admissions, Nursing Stations, Pharmacy, Medical...ing materials includes many products that are fitt...
...MediCopia is a system for inpatient caregiving tha...a's automated computer system offers four technolo...are a handheld computer (for work order processing...cation), thermal printer (for label generation at ...
For superior bar code scanning performance with maximum user comfort at a highly attractive price, the LS 4000i Scanner Series from Symbol Technologies establishes an award-winning standard of excell
The IMAGETEAM 4600 SR / SF area imager from Hand Held Products combines the versatility of area imaging with the speed and cost of linear scanning for healthcare, retail and commercial applications.
Medicine Products: